Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis
Publication: Journal of Comparative Effectiveness Research
Abstract
Aim: To compare the efficacy of ofatumumab to other disease-modifying therapies (DMTs) for relapsing multiple sclerosis (RMS). Materials & methods: A network meta-analysis was conducted to determine the relative effect of ofatumumab on annualized relapse rate and confirmed disability progression at 3 months and 6 months. Results: For each outcome, ofatumumab was as effective as other highly efficacious monoclonal antibody DMTs (i.e., alemtuzumab, natalizumab and ocrelizumab). Conclusion: Ofatumumab offers beneficial outcomes for RMS by reducing relapse and disability progression risk.
Supplementary Material
File (supplementary materials.pdf)
- Download
- 3.27 MB
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
National Multiple Sclerosis Society. Definition of MS (2020). http://www.nationalmssociety.org/What-is-MS/Definition-of-MS
2.
Lublin FD, Reingold SC, Cohen JA et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83(3), 278–286 (2014).
• It provides standardized descriptions of multiple sclerosis disease phenotypes and terminology regarding disease progression.
3.
Tremlett H, Yinshan Z, Devonshire V. Natural history of secondary-progressive multiple sclerosis. Mult. Scler. 14(3), 314–324 (2008).
4.
Scalfari A, Neuhaus A, Daumer M, Muraro PA, Ebers GC. Onset of secondary progressive phase and long-term evolution of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 85(1), 67–75 (2014).
5.
Scolding N, Barnes D, Cader S et al. Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Pract. Neurol. 15(4), 273–279 (2015).
6.
The Lancet. End of the road for daclizumab in multiple sclerosis. Lancet 391(10125), 1000 (2018).
7.
Montalban X, Gold R, Thompson AJ et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult. Scler. 24(2), 96–120 (2018).
8.
Zhang B. Ofatumumab. MAbs 1(4), 326–331 (2009).
9.
Bar-Or A, Grove RA, Austin DJ et al. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: the MIRROR study. Neurology 90(20), e1805–e1814 (2018).
10.
Hauser SL, Bar-Or A, Cohen JA et al. Ofatumumab versus teriflunomide in multiple sclerosis. N. Engl. J. Med. 383(6), 546–557 (2020).
•• It reports efficacy and safety results of the pivotal ofatumumab Phase III trials for relapsing multiple sclerosis.
11.
National Institute for Health and Care Excellence. Single technology appraisal: user guide for company evidence submission template. (2017). https://www.nice.org.uk/process/pmg24/chapter/instructions-for-companies
12.
Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann. Intern. Med. 151(4), 264–269 (2009).
• It describes a widely used protocol for conducting systematic literature reviews.
13.
McCool R, Wilson K, Arber M et al. Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis. Mult. Scler. Relat. Disord. 29, 55–61 (2019).
• It is the most recent systematic literature review and meta-analysis of disease-modifying therapies for relapsing multiple sclerosis.
14.
Centre for Reviews and Dissemination. Systematic Reviews: CRD's Guidance for Undertaking Reviews in Health Care. University of York, York, UK (2009).
15.
Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res. Synth. Methods 3(2), 80–97 (2012).
• It provides guidance for conducting network meta-analyses of randomised controlled trials.
16.
Hoaglin DC, Hawkins N, Jansen JP et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health 14(4), 429–437 (2011).
17.
Jansen JP, Fleurence R, Devine B et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 14(4), 417–428 (2011).
18.
Jansen JP, Naci H. Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. BMC Med. 11(1), 159 (2013).
19.
Hauser SL, Bar-Or A, Comi G et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N. Engl. J. Med. 376(3), 221–234 (2017).
20.
Dias S, Sutton AJ, Ades A, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med. Decis. Making 33(5), 607–617 (2013).
•• It provides guidance for conducting network meta-analyses of randomized controlled trials.
21.
Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res. Synth. Methods 1(2), 97–111 (2010).
22.
Salanti G, Ades A, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J. Clin. Epidemiol. 64(2), 163–171 (2011).
23.
Spiegelhalter D, Thomas A, Best N. WinBUGS user manual. MRC Biostat Unit. (2004). https://www.mrc-bsu.cam.ac.uk/wp-content/uploads/manual14.pdf
24.
Watkins C, Bennett I. A simple method for combining binomial counts or proportions with hazard ratios for evidence synthesis of time-to-event data. Res. Synth. Methods 9(3), 352–360 (2018).
25.
Cree BaC, Corboy J, Singer B et al. Efficacy and safety of fingolimod versus glatiramer acetate in patients with relapsing-remitting multiple sclerosis in the ASSESS study. Presented at: 2019 Consortium of Multiple Sclerosis Centers Annual Meeting. Seattle, WA, USA, 28 May–1 June 2019.
26.
Calabresi PA, Kieseier BC, Arnold DL et al. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, Phase III, double-blind study. Lancet Neurol. 13(7), 657–665 (2014).
27.
National Institute for Health and Care Excellence. Technology appraisal guidance TA533: ocrelizumab for treating relapsing-remitting multiple sclerosis. (2018). https://www.nice.org.uk/guidance/ta533
28.
Durelli L, Verdun E, Barbero P et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 359(9316), 1453–1460 (2002).
29.
Vartanian T. An examination of the results of the EVIDENCE, INCOMIN, and Phase III studies of interferon beta products in the treatment of multiple sclerosis. Clin. Ther. 25(1), 105–118 (2003).
30.
Boiko AN, Lashch NY, Sharanova SN et al. A comparative placebo-controlled clinical trial of the efficacy and safety of glatiramer acetate 20 mg in patients with remitting multiple sclerosis: first-year study results. Neurosci. Behav. Physiol. 48(3), 351–357 (2018).
31.
Haute Autorité De Santé. Commission de la Transparence: alemtuzumab. (2016). https://www.has-sante.fr/jcms/c_2590010/fr/lemtrada-alemtuzumab-immunosuppresseur-selectif
32.
Siddiqui MK, Khurana IS, Budhia S, Hettle R, Harty G, Wong SL. Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis. Curr. Med. Res. Opin. 34(8), 1361–1371 (2018).
33.
Samjoo IA, Salvo EM, Tran D, Amass L, Stewart M, Cameron C. The impact of clinical heterogeneity on conducting network meta-analyses in transthyretin amyloidosis with polyneuropathy. Curr. Med. Res. Opin. 36(5), 799–808 (2020).
34.
Cameron C, Hutton B, Druchok C et al. Importance of assessing and adjusting for cross-study heterogeneity in network meta-analysis: a case study of psoriasis. J. Comp. Eff. Res. 7(11), 1037–1051 (2018).
35.
Cameron C, Ewara E, Wilson FR et al. The importance of considering differences in study design in network meta-analysis: an application using anti-tumor necrosis factor drugs for ulcerative colitis. Med. Decis. Making 37(8), 894–904 (2017).
36.
Cope S, Zhang J, Saletan S, Smiechowski B, Jansen JP, Schmid P. A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer. BMC Med. 12(1), 93 (2014).
• It provides guidance for assessing the feasibility of a network meta-analysis, with an included case study.
37.
Institute for Clinical and Economic Review. Disease-modifying therapies for relapsing-remitting and primary-progressive multiple sclerosis: effectiveness and value. (2017). https://icer-review.org/wp-content/uploads/2016/08/CTAF_MS_Final_Report_030617.pdf
38.
Lucchetta RC, Tonin FS, Borba HHL et al. Disease-modifying therapies for relapsing-remitting multiple sclerosis: a network meta-analysis. CNS Drugs 32(9), 813–826 (2018).
39.
Fogarty E, Schmitz S, Tubridy N, Walsh C, Barry M. Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: systematic review and network meta-analysis. Mult. Scler. Relat. Disord. 9, 23–30 (2016).
40.
Huisman E, Papadimitropoulou K, Jarrett J et al. Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis. BMJ Open 7(3), e013430 (2017).
41.
Melendez-Torres G, Auguste P, Armoiry X et al. Clinical and cost-effectiveness of beta interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation. Health Technol. Assess. 21(52), 1–352 (2017).
42.
Tolley K, Hutchinson M, You X et al. A network meta-analysis of efficacy and evaluation of safety of subcutaneous pegylated interferon beta-1a versus other injectable therapies for the treatment of relapsing-remitting multiple sclerosis. PLoS ONE 10(6), e0127960 (2015).
43.
Tramacere I, Del Giovane C, Salanti G, D'Amico R, Filippini G. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Cochrane Database Syst. Rev. (9), CD011381 (2015).
44.
Tsivgoulis G, Katsanos AH, Grigoriadis N et al. The effect of disease modifying therapies on disease progression in patients with relapsing-remitting multiple sclerosis: a systematic review and meta-analysis. PLoS ONE 10(12), e0144538 (2015).
45.
CAMMS223 Trial Investigators. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N. Engl. J. Med. 359(17), 1786–1801 (2008).
46.
Cohen JA, Coles AJ, Arnold DL et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled Phase III trial. Lancet 380(9856), 1819–1828 (2012).
47.
Coles AJ, Twyman CL, Arnold DL et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled Phase III trial. Lancet 380(9856), 1829–1839 (2012).
48.
Calabrese M, Bernardi V, Atzori M et al. Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis. Mult. Scler. 18(4), 418–424 (2012).
49.
Stępień A, Chalimoniuk M, Lubina-Dąbrowska N, Chrapusta SJ, Galbo H, Langfort J. Effects of interferon beta-1a and interferon beta-1b monotherapies on selected serum cytokines and nitrite levels in patients with relapsing-remitting multiple sclerosis: a 3-year longitudinal study. Neuroimmunomodulation 20(4), 213–222 (2013).
50.
Bornstein MB, Miller A, Slagle S et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N. Engl. J. Med. 317(7), 408–414 (1987).
Information & Authors
Information
Published In
Pages: 1255 - 1274
PubMed: 33090003
Copyright
© 2020 Chris Cameron. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License
History
Received: 22 June 2020
Accepted: 28 September 2020
Published online: 22 October 2020
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis. (2020) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2020-0122
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- David Paling, David Cottrell, Ruth Hamlin, Colin O’Leary, Owen Pearson, Agne Straukiene, Pyry Kivi, Wendy Rice, Sarah Al-Azki, Nazanin Kondori, Real-world evidence of clinical outcomes and adherence to ofatumumab in the UK and the impact of a patients support programme: A retrospective, non-interventional cohort study, Multiple Sclerosis and Related Disorders, 10.1016/j.msard.2026.107030, 107, (107030), (2026).
- Elizabeth Wilson, Tanuja Chitnis, Disease-modifying therapy in pediatric multiple sclerosis, Immunotherapies for Neurologic Diseases, 10.1016/B978-0-323-90887-0.00001-8, (245-254), (2026).
- Alicja Kalinowska, The long-term safety of ofatumumab in multiple sclerosis, Aktualności Neurologiczne, 10.15557/AN.2025.0019, 25, 3, (113), (2025).
- Igor Selmaj, Krzysztof Selmaj, Ofatumumab – long-term efficacy in relapsing multiple sclerosis, Aktualności Neurologiczne, 10.15557/AN.2025.0018, 25, 3, (107), (2025).
- Gina Ferrazzano, Roberta Fantozzi, Shalom Haggiag, Doriana Landi, Francesca Napoli, Maria Chiara Buscarinu, Leonardo Malimpensa, Assunta Bianco, Giovanna Borriello, Elena Barbuti, Fabiana Marinelli, Fabrizia Monteleone, Francesca Marchione, Nicola Falcone, Marta Altieri, Giorgio Leodori, Daniele Belvisi, Fabio Buttari, Valeria Pozzilli, Alessandra Cicia, Antonio Cortese, Francesco Sica, Anna Chiara Landi, Elisabetta Ferraro, Carlo Pozzilli, Massimiliano Mirabella, Carla Tortorella, Girolama Alessandra Marfia, Diego Centonze, Marco Salvetti, Antonella Conte, Real-World 24-Month Outcomes of Ofatumumab in Relapsing Multiple Sclerosis: Efficacy, Safety, and the Impact of Frailty, Neurology and Therapy, 10.1007/s40120-025-00818-7, 14, 6, (2313-2325), (2025).
- Luca Prosperini, Vincenzo Brescia Brescia Morra, Carla Fornari, Laura Santoni, Daria Perini, Roberto Bergamaschi, Paolo Angelo Cortesi, Cost-Consequence Analysis of Natalizumab Compared with Other High-Efficacy Treatments in Patients with Relapsing–Remitting Multiple Sclerosis, PharmacoEconomics, 10.1007/s40273-025-01539-3, 43, 12, (1463-1477), (2025).
- Bruno M. Barros, Marcelo G. Correia, Bernardo R. Tura, Carlos S. Magliano, Cost-Utility Analysis and Efficiency Frontier of Drugs Available in Brazil for the Treatment of Relapsing-Remitting Multiple Sclerosis, Value in Health Regional Issues, 10.1016/j.vhri.2025.101092, 48, (101092), (2025).
- Jihad Inshasi, Yomna Nowier, Evelina A. Zimovetz, Ahmed Moussa, Ahmed Shatila, Ali Hassan, Mohamed Farghaly, Mona Thakre, Mustafa Shakra, Sara Al Dallal, Suzan I. A. Noori, Tayseer Zain Alabdin, Sherouq Khattab, Bassem Yamout, Cost-effectiveness of ofatumumab for the treatment of relapsing forms of multiple sclerosis in the United Arab Emirates, Therapeutic Advances in Neurological Disorders, 10.1177/17562864251330260, 18, (2025).
- M.N. Zakharova, T.O. Simaniv, K.V. Sapozhnikov, D.G. Tolkacheva, V.D. Sokolova, N.A. Sableva, O.N. Mironenko, A.A. Lazarev, T.V. Khimich, Comparing the efficacy of divozilimab and second-line treatments for relapsing-remitting multiple sclerosis in the Russian Federation: a systematic review and network meta-analysis, S.S. Korsakov Journal of Neurology and Psychiatry, 10.17116/jnevro202512502158, 125, 2, (58), (2025).
- Ziyad Almalki, Mashael Alshammari, Saja Almazrou, Ohud Alqahtani, Maryam Alkhayat, Shahad Alnemari, Haya Mukhemair, Sara Alkredeas, Abdulrahman Alsuhibani, Bushra Asiri, Tala Alalawi, Abdullah Alahmari, Fahad Alotaibi, Cost-Effectiveness Analysis of Ofatumumab versus Teriflunomide for Relapsing-Remitting Multiple Sclerosis: A 10-Year Markov Model, ClinicoEconomics and Outcomes Research, 10.2147/CEOR.S503842, Volume 17, (217-232), (2025).
- See more